Neurelis

Neurelis was founded in 2007 with a vow to provide progressive solutions in therapeutic care to address unmet needs. The company was formed in San Diego to address unmet needs for central nervous system disorders. It licenses, develops, and commercializes product candidates for the broader central nervous system (CNS), including epilepsy and psychiatry. Neurelis has developed technologies such as Intravail® and ProTek® to enhance drug delivery and stability.

Neurelis was founded in 2007 with a vow to provide progressive solutions in therapeutic care to address unmet needs. It was formed in San Diego to address unmet needs for central nervous system disorders. The company licensed Intravail® absorption enhancement technology from Aegis Therapeutics, LLC. Over time, it explored various formulations, initiated clinical trials, received orphan drug designation and fast track designation from the FDA, filed a New Drug Application, and acquired Aegis Therapeutics, LLC.

1. Neurelis® Science & Technologies: Innovation Through Technology
2. About Neurelis®: Learn About Our Normal in Therapeutics
3. Neurelis, Inc.: Leadership in Pharmaceuticals
4. Neurelis Board of Directors: Driven to Achieve Progress in Biotech
5. Neurelis (United States)